Guided Internet-Based Treatment for Harmful Alcohol Use; EBehandling Alkohol
Launched by SYKEHUSET I VESTFOLD HF · Dec 12, 2024
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called eBehandling Alkohol (eBA), is studying a new online treatment program designed to help people who struggle with harmful alcohol use. Starting in autumn 2024, this program will be available at five hospitals. The goal is to see how effective this internet-based treatment is in reducing alcohol use and improving overall health and well-being. Previous studies have shown promising results, indicating that this type of treatment can be helpful for many individuals, particularly those who may feel embarrassed or reluctant to seek help in traditional settings.
To participate, individuals must be aged 18 and older, have harmful alcohol use, and be willing to work on reducing their drinking. They should also be comfortable using the internet and have access to a computer, tablet, or smartphone. Importantly, there’s no need for a referral from a doctor to join. After an initial screening, participants will complete nine online treatment modules over the course of 8 to 12 weeks. During this time, and for two years after completing the program, participants will receive follow-up support and answer questions about their progress. This trial aims to help develop better treatment options for those facing alcohol-related issues and is part of a larger effort to understand how internet-based treatments can be more widely used.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Harmful alcohol use
- • Willing to make an effort to reduce alcohol consumption
- • Able to use guided internet-based treatment
- • Access to a computer, tablet, or smartphone
- • Access to BankID or equivalent secure log-in
- Exclusion Criteria:
- • \* Acute and/or severe mental disorders, such as psychotic issues or ongoing suicidal issues.
About Sykehuset I Vestfold Hf
Sykehuset i Vestfold HF is a leading healthcare institution located in Vestfold, Norway, dedicated to providing high-quality medical care and advancing clinical research. As a prominent clinical trial sponsor, the organization is committed to enhancing patient outcomes through innovative research initiatives and collaboration with various stakeholders in the medical and scientific communities. With a focus on ethical standards and regulatory compliance, Sykehuset i Vestfold HF aims to contribute to the development of new therapies and treatment protocols, ensuring that its research efforts are aligned with the needs of patients and the broader healthcare landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Trondheim, , Norway
Tønsberg, Vestfold, Norway
Loerenskog, Akershus, Norway
Trondheim, Trøndelag, Norway
Kristiansand, Agder, Norway
Lillehammer, Innlandet, Norway
Patients applied
Trial Officials
Kristin K Solli, PhD
Principal Investigator
Sykehuset i Vestfold HF
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported